Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immune Design CS (IMDZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 167,811
  • Shares Outstanding, K 25,620
  • Annual Sales, $ 13,260 K
  • Annual Income, $ -53,530 K
  • 36-Month Beta 2.77
  • Price/Sales 15.84
  • Price/Cash Flow 0.00
  • Price/Book 2.85

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.38 +2.23%
on 10/19/17
11.10 -50.43%
on 10/04/17
-4.40 (-44.44%)
since 09/19/17
3-Month
5.38 +2.23%
on 10/19/17
13.05 -57.85%
on 07/27/17
-3.65 (-39.89%)
since 07/19/17
52-Week
4.50 +22.22%
on 11/03/16
13.05 -57.85%
on 07/27/17
-1.50 (-21.43%)
since 10/19/16

Most Recent Stories

More News
Immune Design Announces G100's Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin's Lymphoma

Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation for G100, Immune Design's...

IMDZ : 5.50 (-16.03%)
Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug

Key highlights include regulatory updates from Exelixis (EXEL) and Spark Therapeutics and pipeline updates from Regeneron and Ionis among others.

ONCE : 80.79 (-1.48%)
IMDZ : 5.50 (-16.03%)
IONS : 63.66 (-0.36%)
EXEL : 27.46 (-0.25%)
REGN : 440.94 (+0.36%)
ALXN : 140.46 (+0.16%)
BIIB : 342.42 (-0.63%)
Immune Design's Sarcoma Candidate to Enter Phase III in 2018

Immune Design (IMDZ) plans to initiate a pivotal phase III study to support a Biologics License Application (BLA) for CMB305.

CELG : 135.96 (-0.88%)
NVO : 50.68 (+1.10%)
IMDZ : 5.50 (-16.03%)
ADAP : 7.10 (+1.00%)
Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients

-- CMB305 Monotherapy vs. Placebo in the Maintenance Setting

IMDZ : 5.50 (-16.03%)
Immune Design Announces Four Upcoming Presentations at the SITC 32nd Annual Meeting

Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that four abstracts have been accepted for presentation at the Society for Immunotherapy of Cancer...

IMDZ : 5.50 (-16.03%)
Why Is Immune Design (IMDZ) Down 6.8% Since the Last Earnings Report?

Immune Design (IMDZ) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMDZ : 5.50 (-16.03%)
New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response

-- Phase 2 Interim Analysis Data Presented at ESMO 2017 Congress

IMDZ : 5.50 (-16.03%)
Holding for Harvey

Holding for Harvey

SGMO : 13.95 (-1.41%)
FCAU : 16.53 (-5.60%)
GES : 16.26 (-0.31%)
BLUE : 139.45 (+0.25%)
IMDZ : 5.50 (-16.03%)
CBG : 40.01 (+0.13%)
AAN : 42.48 (+2.93%)
JUNO : 43.40 (+0.74%)
Spectrum (SPPI) Q2 Loss Narrower than Expected, Sales Beat

Spectrum Pharmaceuticals. (SPPI) reported narrower than expected sales and also beat sales expectations. The shares of the company were up due to positive pipeline updates.

SPPI : 18.61 (-5.39%)
SMMT : 11.95 (+0.34%)
IMDZ : 5.50 (-16.03%)
ECYT : 4.97 (+1.22%)
Shire (SHPG) Beats on Q2 Earnings & Sales, Updates '17 View

Shire plc (SHPG) product sales soared in the second quarter on the back of legacy Baxalta sales. However, generic competition is expected to negatively impact full year revenues.

SMMT : 11.95 (+0.34%)
IMDZ : 5.50 (-16.03%)
ECYT : 4.97 (+1.22%)
SHPG : 147.82 (+1.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on the development of immune-based therapies based on its DCVex (TM) and GLAAS (TM) discovery platforms for cancer and other chronic conditions. Its product candidates in Phase I clinical trials comprise LV305, CMB305,...

See More

Support & Resistance

2nd Resistance Point 6.98
1st Resistance Point 6.24
Last Price 5.50
1st Support Level 5.07
2nd Support Level 4.64

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart